Logo image of ABOS

ACUMEN PHARMACEUTICALS INC (ABOS) Stock Fundamental Analysis

NASDAQ:ABOS - Nasdaq - US00509G2093 - Common Stock - Currency: USD

0.98  -0.08 (-7.55%)

Premarket: 0.9741 -0.01 (-0.6%)

Fundamental Rating

1

Overall ABOS gets a fundamental rating of 1 out of 10. We evaluated ABOS against 568 industry peers in the Biotechnology industry. ABOS may be in some trouble as it scores bad on both profitability and health. ABOS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ABOS has reported negative net income.
In the past year ABOS has reported a negative cash flow from operations.
In the past 5 years ABOS always reported negative net income.
In the past 5 years ABOS always reported negative operating cash flow.
ABOS Yearly Net Income VS EBIT VS OCF VS FCFABOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ABOS has a Return On Assets (-42.82%) which is comparable to the rest of the industry.
With a decent Return On Equity value of -56.28%, ABOS is doing good in the industry, outperforming 61.80% of the companies in the same industry.
Industry RankSector Rank
ROA -42.82%
ROE -56.28%
ROIC N/A
ROA(3y)-27.46%
ROA(5y)-40.85%
ROE(3y)-29%
ROE(5y)-46.88%
ROIC(3y)N/A
ROIC(5y)N/A
ABOS Yearly ROA, ROE, ROICABOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

ABOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABOS Yearly Profit, Operating, Gross MarginsABOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for ABOS has been increased compared to 1 year ago.
The number of shares outstanding for ABOS has been increased compared to 5 years ago.
The debt/assets ratio for ABOS is higher compared to a year ago.
ABOS Yearly Shares OutstandingABOS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
ABOS Yearly Total Debt VS Total AssetsABOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ABOS has an Altman-Z score of -2.10. This is a bad value and indicates that ABOS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.10, ABOS is in line with its industry, outperforming 54.93% of the companies in the same industry.
A Debt/Equity ratio of 0.16 indicates that ABOS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.16, ABOS is doing worse than 69.19% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z -2.1
ROIC/WACCN/A
WACCN/A
ABOS Yearly LT Debt VS Equity VS FCFABOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 6.46 indicates that ABOS has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.46, ABOS is doing good in the industry, outperforming 66.20% of the companies in the same industry.
ABOS has a Quick Ratio of 6.46. This indicates that ABOS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.46, ABOS is in the better half of the industry, outperforming 66.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.46
Quick Ratio 6.46
ABOS Yearly Current Assets VS Current LiabilitesABOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ABOS have decreased strongly by -58.33% in the last year.
EPS 1Y (TTM)-58.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-121.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ABOS is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.90% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-34.91%
EPS Next 2Y0.55%
EPS Next 3Y-3.34%
EPS Next 5Y-3.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ABOS Yearly Revenue VS EstimatesABOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2028 2029 2030 2031 2032 100M 200M 300M
ABOS Yearly EPS VS EstimatesABOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ABOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABOS Price Earnings VS Forward Price EarningsABOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABOS Per share dataABOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A cheap valuation may be justified as ABOS's earnings are expected to decrease with -3.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.55%
EPS Next 3Y-3.34%

More info and screens

0

5. Dividend

5.1 Amount

ABOS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACUMEN PHARMACEUTICALS INC

NASDAQ:ABOS (4/22/2025, 8:00:00 PM)

Premarket: 0.9741 -0.01 (-0.6%)

0.98

-0.08 (-7.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/bmo
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners75.55%
Inst Owner Change-0.04%
Ins Owners6.18%
Ins Owner Change7.96%
Market Cap59.36M
Analysts86.67
Price Target8.93 (811.22%)
Short Float %3.39%
Short Ratio6.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.47%
Min EPS beat(2)-34.3%
Max EPS beat(2)-26.63%
EPS beat(4)1
Avg EPS beat(4)-18.56%
Min EPS beat(4)-34.3%
Max EPS beat(4)5.73%
EPS beat(8)4
Avg EPS beat(8)-3.37%
EPS beat(12)4
Avg EPS beat(12)-8.05%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-18.98%
PT rev (3m)-18.98%
EPS NQ rev (1m)-15.27%
EPS NQ rev (3m)-15.27%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.33
P/tB 0.33
EV/EBITDA N/A
EPS(TTM)-1.71
EYN/A
EPS(NY)-2.31
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS0
BVpS3
TBVpS3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.82%
ROE -56.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.46%
ROA(5y)-40.85%
ROE(3y)-29%
ROE(5y)-46.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.43%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.46
Quick Ratio 6.46
Altman-Z -2.1
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-121.43%
EPS Next Y-34.91%
EPS Next 2Y0.55%
EPS Next 3Y-3.34%
EPS Next 5Y-3.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-86.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-80.26%
EBIT Next 3Y-35.59%
EBIT Next 5Y-30.7%
FCF growth 1Y-22.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.51%
OCF growth 3YN/A
OCF growth 5YN/A